SUMMARY The immunoperoxidase staining of 84 primary invasive breast carcinomas with four monoclonal antibodies (BRST-1, HMFG1, EMA, B72-3) was evaluated by semiquantitative light microscopical examination and quantitative image analysis. Major differences in the staining of the tumours for each of the monoclonal antibodies was observed. Correlation between monoclonal antibody staining and patient age, survival, histological grade, tumour diameter and cellularity was also carried out. This showed a significant association between histological grade and staining with BRST-1 and EMA.
The potential value of monoclonal antibodies in cancer has been widely investigated, and the immunoperoxidase localisation of monoclonal antibodies applied to tissue sections has found several applications.' These include determination of the origin ofmetastatic tumours, the differential diagnosis of undifferentiated neoplasms, and the functional classification of malignancies. Other applications include the use of monoclonal antibodies to detect occult metastases or determine prognosis, and it is these roles that have attracted most attention in breast cancer. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Monoclonal antibodies reactive against breast carcinoma have been produced using several different immunogens. These include breast carcinoma metastases, milk fat globule membranes, breast carcinoma cell lines, lymph nodes from patients who have had a mastectomy, cytoplasmic intermediate filaments and receptor proteins. '3 In this study we critically evaluated staining with four commercially available monoclonal antibodies, using both semiquantitative light microscopical examination and quantitative image analysis to minimise subjective bias.
Material and methods
Immunohistochemical staining was carried out on 84 cases of primary mammary carcinoma (ductal' not otherwise specified) diagnosed and treated in Maryfield Hospital and Dundee Royal Infirmary in Accepted for publication 31 March 1989 1972 or 1973. Patient characteristics have previously been described'2 and follow up for this study stopped in June 1987. Formalin fixed, paraffin wax embedded sections cut at 5 gm were used. Sections for each monoclonal antibody were stained in a single batch to exclude any inherent variation in staining that inevitably arises between different batches of slides. The monoclonal antibodies used were BRST-I (Ortho), HMFGI (Oxoid), EMA (Dako), and B72-3 (Biogenesis). A preliminary study was carried out to determine the optimal concentrations of monoclonal antibody for staining.
Antibodies were localised by the avidin-biotin peroxidase label method (Vector Laboratories), '4 binding resulting in a brown reaction product following oxidation of diaminobenzidine. (table 3) . This was confined to assessment by the Quantimet and by visual assessment of membrane staining. A similar negative correlation was observed between membrane staining by EMA and histological grade (-041, p < 0-001). Apart from these findings, no significant correlation was observed between monoclonal antibody staining and survival, age, tumour diameter or cellularity (data not shown). Extracellular staining showed no correlation between any ofthe variables assessed. The formation ofa staining index derived from a combination of the cytoplasm and membrane scores did not change the above findings.
Discussion
Most of the neoplasms stained with each of the four monoclonal antibodies and this accords with previous studies.89" 2 The poorest staining was observed with B72.3 when only 68 out of 81 tumours were positive. Our results show considerable differences in staining among different monoclonal antibodies in the group of breast neoplasms studied. These differences are most easily appreciated by studying the results obtained from the Quantimet. There was a good Parham, Coghill, Robertson correlation between the Quantimet assessment of monoclonal antibody staining and membrane or cytoplasmic staining determined visually. No correlation, however, was observed between extracellular staining and all of the variables measured. Extracellular staining formed only a minor part of total tumour staining and was difficult to quantify reliably by light microscopical examination. Furthermore, staining deposits tended to occur in areas where the pattern of fibrosis suggested recent necrosis and as such probably does not represent true extracellular secretion.
Two of the antibodies used were raised against milk fat globule membranes (HMFG1, anti-EMA),2 22 one was raised against cell membranes derived from breast carcinoma metastases (B72.3)'8 and the fourth against a breast carcinoma cell line (BRSTl).20 Little is known about the relations of the epitopoes against which these monoclonal antibodies are directed, but all are immunoreactive against glycoproteins320 2325 present in the cell cytoplasm and on cell membranes. It is thought that HMFG1 reacts against a different antigenic site on the same molecule to which EMA is directed.26 The other monoclonal antibodies may have a similar relation with this molecule. This would explain the positive correlation between EMA expression and the staining by other antibodies. If the antigen determinant to which EMA is directed also has a central role in the formation of this molecule, and the other epitopes are more variable and more vulnerable to the malignant process, this would explain the poorer correlation observed in staining among the other monoclonal antibodies.
A significant negative correlation was observed between BRST-1 (Quantimet and membrane) staining and tumour differentiation, as assessed by histological grade. BRST-1 staining was greatest in well differentiated tumours (grade 1) and least in poorly differentiated ones (grade 3). EMA staining ofcell membranes was also related to differentiation, although this only just reached significance. No correlation between staining by any of the monoclonal antibodies and survival was observed.
The absence ofany association between monoclonal antibody expression and survival was not unexpected.
A previous study found that absence of HMFG1 expression was associated with a poor prognosis and extracellular deposits with a favourable outcome when correlated against remission.8 Other authors, however, were unable to show any association with patient survival.912 Ellis et al, using a monoclonal antibody (NCRC 11) raised to human milk fat globule membrane, found a positive correlation between the degree of staining and survival.2"2 Wright et al were unable to reproduce these findings.30 Possible explanations for the lack of consistency in these studies may include variations among laboratories in the preparation of stained tissue sections and the methods of patient follow up.
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